ABT · Business segments
Abbott (ABT) revenue by segment
Where Abbott’s revenue comes from, as reported in its SEC filings.
Latest quarter: June 30, 2026
Total revenue on the income statement: $12.59B.
Revenue by Segment
| Line | Revenue | Share | Operating income | Margin |
|---|---|---|---|---|
| Medical Devices | $5.85B | 46.5% | $1.97B | 33.6% |
| Diagnostic Products | $3.09B | 24.6% | $499M | 16.1% |
| Nutritional Products | $2.14B | 17.0% | $368M | 17.2% |
| Established Pharmaceutical Products | $1.5B | 11.9% | $382M | 25.5% |
Revenue by Geography
| Line | Revenue | Share |
|---|---|---|
| Non-US | $7.38B | 58.6% |
| United States | $5.22B | 41.4% |
Latest year: December 31, 2025
Total revenue on the income statement: $44.33B.
Revenue by Geography
| Line | Revenue | Share |
|---|---|---|
| United States | $17.13B | 38.6% |
| All Other Countries | $15.98B | 36.0% |
| Germany | $2.76B | 6.2% |
| China | $1.91B | 4.3% |
| India | $1.87B | 4.2% |
| Switzerland | $1.87B | 4.2% |
| Japan | $1.48B | 3.3% |
| United Kingdom | $1.34B | 3.0% |
Revenue by Segment
| Line | Revenue | Share | Operating income | Margin |
|---|---|---|---|---|
| Medical Devices | $21.39B | 48.3% | $7.21B | 33.7% |
| Diagnostic Products | $8.94B | 20.2% | $1.74B | 19.5% |
| Nutritional Products | $8.45B | 19.1% | $1.56B | 18.4% |
| Established Pharmaceutical Products | $5.54B | 12.5% | $1.29B | 23.3% |
Reading notes
Share is each line’s part of that breakdown. Margin is the company’s reported segment operating income divided by that segment’s revenue. Companies define segment profit differently and may re-cut segments over time, so a company’s lines can differ between years. Breakdowns that do not add up to within 5% of reported revenue are left out.